- Trial phase
- Approved
- Time to market
- Already on the market since August 2023 under accelerated approval for 4th-line-plus relapsed/refractory multiple myeloma. Pfizer plans to submit the MagnetisMM-32 data to global health authorities to seek label expansion into earlier treatment lines, but no specific regulatory filing or PDUFA date has been announced.
- Why 4/10
- Elrexfio is already approved and commercializing; no hard dated binary catalyst (PDUFA or pivotal readout) is scheduled in the next ~12 months. Pfizer plans to submit Phase 3 MagnetisMM-32 data to regulators for label expansion, but no submission or decision date has been set. The drug is one of many products in Pfizer's massive $62-64B revenue portfolio, so even a label expansion would be a modest contributor to the stock.
Watch for Pfizer's regulatory submission of the MagnetisMM-32 data to the FDA, which would trigger a PDUFA clock for label expansion into earlier-line multiple myeloma. Also monitor the MagnetisMM-7 readout in newly diagnosed post-transplant patients. The key question is whether Elrexfio can carve out meaningful market share against J&J's entrenched Tecvayli franchise as it moves into earlier treatment lines.
Price Chart
Executive Summary
Elrexfio (elranatamab) is Pfizer's off-the-shelf BCMA-targeting bispecific antibody for relapsed/refractory multiple myeloma, approved under accelerated approval in August 2023 for patients after four or more prior therapies. The drug has generated two positive Phase 3 readouts in 2026 (MagnetisMM-5 in April and MagnetisMM-32 in October), both showing statistically significant progression-free survival improvements that could support label expansion into earlier treatment lines. First-half 2026 sales reached $169 million, up 17% year-over-year, but the drug faces stiff competition from Johnson & Johnson's Tecvayli and Talvey, Regeneron's Lynozyfic, and CAR-T therapies. For Pfizer, a $200B+ market cap company with $62-64B in 2026 revenue guidance, Elrexfio is a small but growing contributor within a broad oncology portfolio.
How It Works
A bispecific antibody that works like a bridge: one end grabs onto T cells (a type of immune cell) and the other end grabs onto multiple myeloma cancer cells. This brings the T cells close enough to recognize and kill the cancer cells. It is given as a shot under the skin and is "off-the-shelf" (ready to use, unlike personalized cell therapies).
Trial Status
Elrexfio received accelerated FDA approval in August 2023 based on the Phase 2 MagnetisMM-3 trial (57.7% response rate in heavily pre-treated patients). Two Phase 3 trials have since reported positive topline results: MagnetisMM-5 (April 2026) showed statistically significant PFS improvement versus standard-of-care daratumumab/pomalidomide/dexamethasone in double-class exposed RRMM; MagnetisMM-32 (October 2026) showed statistically significant PFS benefit versus investigator's choice of three standard regimens in patients after anti-CD38 and lenalidomide. Additional Phase 3 trials (MagnetisMM-6, MagnetisMM-7, ElLen) are ongoing in newly diagnosed and post-transplant settings.
The Two-Sided Case
Upcoming Catalysts
- Submission of MagnetisMM-32 data to FDA and other global health authorities for label expansion into earlier-line multiple myeloma (timing not yet specified)
- Detailed MagnetisMM-32 results at a future medical meeting
- Potential MagnetisMM-7 readout in newly diagnosed post-transplant multiple myeloma
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report